Haisco Pharmaceutical Group Co., Ltd.
002653
Classement en actions
#1996
Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates... Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates within China, focusing on the research, production, and distribution of a diverse range of pharmaceutical products. Their offerings span various dosage forms, including small and large volume injections, freeze-dried and conventional powder injections, and active pharmaceutical ingredients (APIs). These medications target numerous therapeutic areas such as anti-infectives, digestive system disorders, blood system conditions, nervous system ailments, parenteral nutrition, antibiotics, emergency care, anesthesiology, and oncology. Furthermore, the company provides drugs in tablet, capsule, granule, and ointment forms for cardiovascular health, infectious diseases, digestive issues, central nervous system (CNS) conditions, diabetes, and hepatic diseases. Established in 2000 and based in Shannan, China, the company adopted its current name, Haisco Pharmaceutical Group Co., Ltd., in March 2016, having previously been known as Xizang Haisco Pharmaceutical Group Co., Ltd.
Prix de l'action
$9.04
Capitalisation boursière
$10.31B
Changement (1 jour)
0.08%
Changement (1 an)
23.85%
Pays
CN
Échange Haisco Pharmaceutical Group Co., Ltd. (002653)
Catégorie
Healthcare
Revenus pour Haisco Pharmaceutical Group Co., Ltd. (002653)
Revenus en Jun 2026 TTM : $794.50M
Selon les derniers rapports financiers de Haisco Pharmaceutical Group Co., Ltd., le chiffre d'affaires actuel de l'entreprise (TTM) est de $794.50M. En 2023, l'entreprise a réalisé un chiffre d'affaires de $473.97M une augmentation par rapport à le chiffre d'affaires de l'année 2022, qui était de $437.13M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Haisco Pharmaceutical Group Co., Ltd. de 2008 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $794.50M | 55.83% |
| 2024 | $509.84M | 7.57% |
| 2023 | $473.97M | 8.43% |
| 2022 | $437.13M | 0.18% |
| 2021 | $436.34M | -14.39% |
| 2020 | $509.68M | -9.86% |
| 2019 | $565.44M | 13.51% |
| 2018 | $498.16M | 74.62% |
| 2017 | $285.29M | 37.97% |
| 2016 | $206.77M | 10.75% |
| 2015 | $186.71M | -4.47% |
| 2014 | $195.45M | 19.47% |
| 2013 | $163.60M | 27.19% |
| 2012 | $128.62M | 34.15% |
| 2011 | $95.88M | 8.81% |
| 2010 | $88.11M | 24.14% |
| 2009 | $70.98M | 36.50% |
| 2008 | $52.00M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | 1,488.97% |
US
|
|
| $2.23B | 180.43% |
US
|
|
| $15.74B | 1,881.68% |
AU
|
|
| $6.02B | 657.88% |
NL
|
|
| - | - |
CH
|
